Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Kanghua Out-Licenses Norovirus Vaccine Candidate to HilleVax in $270 Million Deal

publication date: Jan 10, 2024

Chengdu Kanghua Biological Products (Kangh) out-licensed global (ex-China) rights for its norovirus vaccine candidate to Boston’s HilleVax in a $270 million agreement. Norovirus is the leading cause of gastroenteritis (vomiting and diarrhea). HIL-216 includes virus-like particles (VLPs) for six of the most common norovirus genotypes. In 2021, HilleVax, was formed by Japan’s Takeda Pharma to develop another norovirus vaccine candidate, HIL-214 (formerly TAK-214), outside of Japan. Kangh will receive $15 million up front and up to $255.5 million in milestones, plus single-digit tiered royalties. More details....

Stock Symbols: (SHZ: 300841) (NSDQ: HLVX)

Share this with colleagues: